|Bid||7.00 x 800|
|Ask||10.95 x 1000|
|Day's Range||8.00 - 8.55|
|52 Week Range||4.56 - 17.34|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.33|
Millendo Therapeutics announces the promotion of Thomas Hoover to the newly created position of Chief Commercial Officer
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of Millendo Therapeutics, Inc. (NASDAQ:MLND) based on that […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
– Livoletide pivotal study in Prader-Willi syndrome completed recruitment for patients ages 8 to 65 and is on track to report topline results in 1H20 –
Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced that the Phase 2b portion of its pivotal Phase 2b/3 clinical study of livoletide in patients with Prader-Willi syndrome (PWS), called ZEPHYR, has completed recruitment for patients ages 8 to 65. The study, one of the largest PWS studies ever conducted with over 150 patients recruited across 38 clinical trial sites worldwide, is evaluating the safety and efficacy of livoletide on food-related behaviors in patients with PWS.
Millendo Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that Julia C.
Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that it will host a PWS Breakfast Symposium on Thursday, November 14, 2019 from 8:30 a.m. to 10:30 a.m. EST. The event will feature a clinical and scientific presentation by Shawn E. McCandless, M.D., Professor and Head of Section, Genetics and Metabolism - Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital of Colorado. The Symposium will also include presentations from company management on the current treatment landscape for PWS, the status of Millendo’s development program and the opportunity for livoletide in PWS.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 2) Dova Pharmaceuticals Inc (NASDAQ: DOVA ) Down In The ...
Although Millendo Therapeutics is a newer player in the biotech public market and the PWS market is small, it represents a so-far unmet need, Chico said in the note. About 10,000 patients suffer from PWS in the US, and there are no treatments available for the hallmark syndrome, hyperphagia, the analyst mentioned.
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]
Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that Pharis Mohideen, M.D., is departing the company to pursue a career opportunity closer to his home in New Jersey, allowing him to spend more time with his family. “I am proud to have been Millendo’s Chief Medical Officer, and to have been part of the growth and success of the company for the past five years,” said Dr. Mohideen, “I leave behind an exceptional team, with a promising pipeline and a significant opportunity to have an impact in rare endocrine diseases. Julia C. Owens, Ph.D., President and CEO of Millendo commented, “Pharis has played a critical role in the advancement of our clinical-stage programs and supported the transformation of Millendo to a publicly traded biopharmaceutical company.
Every investor in Millendo Therapeutics, Inc. (NASDAQ:MLND) should be aware of the most powerful shareholder groups...
Millendo Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference in New York City on Thursday, June 6, 2019 at 11:00 a.m.
Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that its late-stage clinical candidates, livoletide and nevanimibe, will be featured in three concurrent poster presentations at the European Society of Endocrinology’s 21st European Congress of Endocrinology (ECE), taking place May 18-21, 2019 in Lyon, France. Livoletide, a potential first-in-class treatment for Prader-Willi syndrome (PWS), will be featured in two poster presentations. The company will provide an overview of the pivotal Phase 2b/3 ZEPHYR clinical trial, initiated in March 2019, to evaluate the safety and efficacy of livoletide for hyperphagia and food-related behaviors in PWS patients in one poster.
2019 SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on Tuesday, May 7, 2019 in New York, where one-on-one investor meetings will be held. Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient.